NCT06333652 Ravulizumab in Pregnancies Complicated by Severe Hypertensive Disorders
| NCT ID | NCT06333652 |
| Status | Recruiting |
| Phase | Phase 2 |
| Sponsor | Mayo Clinic |
| Condition | Preeclampsia |
| Study Type | INTERVENTIONAL |
| Enrollment | 14 participants |
| Start Date | 2026-09-01 |
| Primary Completion | 2028-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 14 participants in total. It began in 2026-09-01 with a primary completion date of 2028-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The researchers are testing a medication named ravulizumab for the treatment of severe preeclampsia and Hemolysis, Elevated Liver enzymes, Low Platelets (HELLP) syndrome.
Eligibility Criteria
Inclusion Criteria: * Individuals with \< 34 0/7 weeks of gestation. * Individuals with severe preeclampsia or HELLP features. Exclusion Criteria: * Pregnant female patients presenting with disseminated intravascular coagulopathy (DIC). * Individuals with non-reassuring fetal status requiring delivery, non-viable fetuses, previable pregnancy (\<23 0/7 weeks gestation), stroke, in utero fetal demise, known atypical hemolytic uremic syndrome, familial or acquired thrombocytopenia purpura, paroxysmal nocturnal hemoglobinuria, allergy to Ravulizumab, inability or unwillingness to sign informed consent.
Contact & Investigator
Gonzalez Suarez
📞 507-284-2511
Maria Lourdes Gonzalez Suarez, MD, PhD
PRINCIPAL INVESTIGATOR
Mayo Clinic
Frequently Asked Questions
Who can join the NCT06333652 clinical trial?
This trial is open to female participants only, aged 18 Years or older, up to 50 Years, studying Preeclampsia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06333652 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT06333652 currently recruiting?
Yes, NCT06333652 is actively recruiting participants. Visit ClinicalTrials.gov or contact Mayo Clinic to inquire about joining.
Where is the NCT06333652 trial being conducted?
This trial is being conducted at Rochester, United States.
Who is sponsoring the NCT06333652 clinical trial?
NCT06333652 is sponsored by Mayo Clinic. The principal investigator is Maria Lourdes Gonzalez Suarez, MD, PhD at Mayo Clinic. The trial plans to enroll 14 participants.